文献速递胸部肿瘤

维生素B6分解代谢与肺癌风险:肺癌队列联盟(LC3)研究结果

Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3).
PubMed 文献 · Ann Oncol · 2019-01-01

基于肺癌队列联盟20个前瞻性队列的5323例肺癌病例与5323例年龄、性别、吸烟状态个体匹配的对照,计算PAr指数与肺癌风险的关联。PAr最高四分位组相比最低四分位组的肺癌风险OR为1.38(95%CI:1.19-1.59),关联在既往吸烟者、男性及采血后3年内诊断的肺癌中更明显。作者认为PAr可能是肺癌的诊断前标志物而非因果因素。

要点

  • PAr指数与肺癌风险呈剂量反应正相关,最高vs最低四分位OR为1.38(95%CI:1.19-1.59)。
  • 既往吸烟者OR为1.69(95%CI:1.36-2.10),男性OR为1.60(95%CI:1.28-2.00)。
  • 采血后3年内诊断的肺癌OR为1.73(95%CI:1.34-2.23)。

核心结论

  • 基于4大洲20个队列的诊断前数据,本研究证实与炎症和免疫激活相关的维生素B6分解代谢增加与肺癌发生风险升高相关。
  • PAr可能是肺癌的诊断前标志物而非因果因素。

研究设计与样本

  • 在肺癌队列联盟的20个前瞻性队列内,按年龄、性别和吸烟状态个体匹配,纳入5323例肺癌病例和5323例对照。
  • 使用条件logistic回归计算各队列PAr与肺癌风险的OR及95%CI,并采用随机效应模型合并。

主要发现

  • PAr与肺癌风险呈剂量反应正相关,PAr第四四分位组对比第一四分位组的总体肺癌风险OR为1.38(95%CI:1.19-1.59)。
  • PAr与肺癌风险的关联在既往吸烟者中最明显,OR为1.69(95%CI:1.36-2.10)。
  • 该关联在男性中OR为1.60(95%CI:1.28-2.00),在采血后3年内诊断的肺癌中OR为1.73(95%CI:1.34-2.23)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. MATERIALS AND METHODS: For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. RESULTS: PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). CONCLUSION: Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Zuo H, Ueland PM, Midttun Ø, et al. Vitamin B6 catabolism and lung cancer risk: results from the Lung Cancer Cohort Consortium (LC3). Ann Oncol. 2019. PMID: 30698666. doi:10.1093/annonc/mdz002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。